#Israel #Rehovot #Evogene #Casterra #AgPlenus

Evogene's Financial Insights for 2024

Evogene Ltd. (NASDAQ EVGN) released its financial results for the fourth quarter and full year of 2024, revealing significant growth and strategic shifts. This computational biology company, known for harnessing AI to advance life-science products, reported total revenues of approximately $8.5 million for 2024, a notable increase from about $5.6 million in 2023. This jump in revenues is primarily attributed to increased sales from Casterra—a subsidiary specializing in castor seed—and the successful collaboration between AgPlenus and Bayer.

Financial Breakdown

In the fourth quarter of 2024, Evogene’s revenues were about $1.6 million, up from roughly $0.6 million during the same period in 2023. While initial estimates anticipated higher figures, adjustments in the delivery schedule of Casterra’s seeds pushed some sales into 2025. Notably, Casterra successfully delivered around 76 tons of seeds in Q4 2024, followed by a whopping 250 tons in February 2025 alone.

Comparatively, total research and development (R&D) expenses for the year amounted to approximately $16.6 million, down from $20.8 million in 2023. The reduction reflects a strategic pivot after ceasing activities with Canonic in mid-2024 and scaling back operations across several subsidiaries. Furthermore, general administrative expenses rose to approximately $7.4 million, driven by transaction costs related to Evogene's fundraising initiatives and provisions for doubtful debts.

Management Insights

Ofer Haviv, President and CEO of Evogene, emphasized the importance of strategic re-alignment in the company’s direction. The announcement of a new Chairperson for the Board, Nir Nimrodi, signals a fresh leadership perspective, while Ms. Sarit Firon remains on board as a member to provide continuity. Haviv articulated confidence in leveraging the ChemPass AI technology for drug discovery and emphasized Evogene's commitment to pursuing collaborations with biotech firms and academic institutions in this area.

Strategic Focus and Future Goals

Evogene aims to solidify its position through several strategic initiatives:

• - Enhancing ChemPass AI to secure partnerships for small-molecule drug discovery.
• - Creating exit events for subsidiaries to inject capital into the parent company’s activities.
• - Strengthening Casterra’s market position, targeting expansion and increased revenues from castor oils, particularly in African markets, and venturing into Brazil.

For 2025, Casterra intends to initiate proof-of-concept trials for crop production and develop new seed varieties that address the evolving market dynamics. Evogene’s subsidiaries, including Lavie Bio and Biomica, are also set to improve their product offerings through ongoing R&D and collaborations.

Financial Resiliency

Despite the challenges posed in recent years, Evogene's cash position as of December 31, 2024, was approximately $15.3 million. The reduction in cash usage to about $10.4 million in the year marks a 17% decrease from 2023. Evogene plans to use profits generated from Casterra to support broader corporate initiatives, contributing towards enhancing its financial health moving forward.

Conclusion

The financial results from Evogene highlight a year of significant transformation, showcasing a commendable rise in revenues paired with a concerted focus on reducing operating expenses and fostering innovation in life sciences. As they head into 2025, the company seems well-positioned to augment its market presence and drive future growth through strategic collaborations and continued tech advancement.